Jildas Munyantore

Jildas Munyantore

Auto-generated profile, based on publicly available information

Jildas Munyantore

Department of General Medicine and Surgery, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
OSOlivier Sibomana
Olivier Sibomana
CHCLYDE HAKAYUWA
CLYDE HAKAYUWA
AOAbraham Obianke
Abraham Obianke
HGHubert Gahire
Hubert Gahire
JMJildas Munyantore
Jildas Munyantore
MCMatimba Molly Chilala
Matimba Molly Chilala
Atrial fibrillation (AF), the most common form of cardiac arrhythmia, is associated with significant morbidity, mortality, and financial burden. Traditional diagnostic methods, such as 12-lead electrocardiograms (ECG), have limitations in detecting intermittent AF episodes. Consequently, smart wearables have been introduced to enhance continuous AF monitoring. This systematic review and meta-analysis aimed to evaluate and compare the diagnostic accuracy of ECG smart chest patches and photoplethysmography (PPG)– based smartwatches in AF detection. From august 16–20, 2024, a comprehensive search was conducted across PubMed/MEDLINE, DOAJ, AJOL, and the Cochrane Library. Original studies assessing the performance of ECG smart chest patches and PPG smartwatches in detecting AF were included. Studies were screened based on predefined inclusion and exclusion criteria, and the most relevant were finally included. For ECG smart chest patches and PPG smartwatches groups, random-effects model was used to pool these performance metrics. Statistical analyses were performed using Jamovi 2.3.28, with a significance threshold of p < 0.05. A total of 15 studies were included in the current systematic review and meta-analysis. ECG smart chest patches demonstrated a pooled sensitivity of 96.1% [(95% CI: 91.3–100.8), (I² = 94.59%)], and a pooled specificity of 97.5% [(95% CI: 94.7–100.2), (I² = 79.1%)]. PPG smartwatches showed a pooled sensitivity of 97.4% [(95% CI: 96.5–98.3), (I² = 3.16%)], and a pooled specificity of 96.6% [(95% CI: 94.9–98.3), (I² = 75.94%)]. Comparatively, both ECG smart chest patches and PPG smartwatches exhibited excellent performance in atrial fibrillation detection, with PPG smartwatches showing slightly higher sensitivity and ECG chest patches exhibiting marginally greater specificity. Both ECG smart chest patches and PPG smartwatches are highly effective for detecting atrial fibrillation. However, further advancements are needed to match their accuracy with that of standard diagnostic methods and achieve comprehensive digital cardiac monitoring.

19 December 2024 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
OSOlivier Sibomana
Olivier Sibomana
CHCLYDE HAKAYUWA
CLYDE HAKAYUWA
JMJildas Munyantore
Jildas Munyantore
Marburg virus disease (MVD) is a highly virulent and often fatal disease caused by the Marburg virus, a member of the Filoviridae family, closely related to the Ebola virus. Historically, outbreaks have been sporadic but lethal across various African countries, with high case fatality rates (CFRs). In 2023, significant outbreaks occurred in Tanzania and Equatorial Guinea, with CFRs of 62.5% and 75%, respectively. In 2024, Rwanda faced its first outbreak, starting on September 27, 2024. By November 8, 2024, Rwanda had conducted 7,408 tests, confirming 66 cases, 15 of which were fatal, and 51 recoveries. Although no approved vaccine currently exists for MVD, global health authorities are prioritizing the development of effective vaccines. Drawing on insights from the rapid COVID-19 vaccine development, several promising candidates are under exploration, with the cAd3-MARV showing notable potential. This paper examines the current MVD outbreak in Rwanda and the progress toward developing a long-term vaccine solution.